The INHA antibody targets the inhibin alpha subunit (INHA), a critical component of the glycoprotein hormone inhibin, which belongs to the TGF-β superfamily. Inhibin exists as a dimer, combining an α-subunit (INHA) with either a βA (INHBA) or βB (INHBB) subunit to form inhibin A or B, respectively. These hormones primarily regulate follicle-stimulating hormone (FSH) secretion by the pituitary gland, playing a key role in reproductive physiology. INHA antibodies are used extensively in research and diagnostics to study inhibin expression patterns, particularly in reproductive disorders such as premature ovarian insufficiency, polycystic ovary syndrome (PCOS), and certain cancers. Elevated inhibin levels, detected via INHA antibodies, serve as biomarkers for ovarian granulosa cell tumors and mucinous carcinomas. Additionally, INHA antibodies help investigate feedback mechanisms in the hypothalamic-pituitary-gonadal axis and explore autoimmune conditions where anti-INHA antibodies may disrupt ovarian function. Their applications extend to immunohistochemistry, ELISA, and Western blotting, aiding both basic research and clinical assays. Recent studies also explore their potential in fertility treatments and cancer immunotherapy, underscoring their multifaceted significance in reproductive and oncological medicine.